Hematuria in anticoagulated patients with atrial fibrillation and urologic cancer

Anne Gulbech Ording; Mette Søgaard; Flemming Skjøth; Erik Lerkevang Grove; Professor Gregory Lip; Torben Bjerregaard Larsen; Peter Brønnum Nielsen

doi:10.1002/rth2.12629

Abstract

1 min read

In patients with AF and urologic cancer, there was a similar risk of hematuria associated with DOAC and warfarin treatment.

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2022

Oral anti‐coagulant treatment patterns in atrial fibrillation patients diagnosed with cancer: A Danish nationwide cohort study

Anne Gulbech Ording, Mette Søgaard, Peter Brønnum Nielsen, Professor Gregory Lip, Torben Bjerregaard Larsen, Erik Lerkevang Grove, Flemming Skjøth

Article2021

Bleeding complications in patients with gastrointestinal cancer and atrial fibrillation treated with oral anticoagulants

Anne Gulbech Ording, Mette Søgaard, Flemming Skjøth, Erik Lerkevang Grove, Professor Gregory Lip, Torben Bjerregaard Larsen, Peter Brønnum Nielsen

Article2017

Outcomes Associated With Resuming Warfarin Treatment After Hemorrhagic Stroke or Traumatic Intracranial Hemorrhage in Patients With Atrial Fibrillation

Peter Brønnum Nielsen, Torben Bjerregaard Larsen, Flemming Skjøth, Professor Gregory Lip

Article2024

Risk of Adverse Events in Anticoagulated Patients With Atrial Fibrillation and Nonalcoholic Fatty Liver Disease

Tommaso Bucci, Katarzyna Nabrdalik, Francesco Baratta, Daniele Pastori, Pasquale Pignatelli, Theresa Hydes, Uazman Alam, Francesco Violi, Professor Gregory Lip

Article2019

P4789Comparisons of direct oral anticoagulants and warfarin in patients with atrial fibrillation and liver cirrhosis

Tze‐Fan Chao, Professor Gregory Lip, S A Chen